FIELD: biotechnology.
SUBSTANCE: invention relates to fusion proteins for application as an immunogenic enhancing agent to enhance antigen-specific T-cell responses, and can be used in medicine. A fusion protein is produced recombinantly, which comprises: (a) a binding domain with an antigen-presenting cell (APC) or a binding domain with the CD91 receptor; (b) a protein transduction domain; (c) a pathogenic antigen. The binding domain with the antigen-presenting cell (APC) or the binding domain with the CD91 receptor is located at the N-terminus of the fusion protein, and the pathogenic antigen is located at the C-terminus of the protein transduction domain.
EFFECT: invention allows to obtain an enhanced antigen-specific T-cell response against a viral pathogen and cancer cell.
16 cl, 15 dwg, 2 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSION PROTEINS FOR APPLICATION AS IMMUNOGENIC AMPLIFYING AGENTS TO INDUCE ANTIGEN-SPECIFIC T-CELL RESPONSE | 2013 |
|
RU2619187C2 |
| VACCINES AGAINST HPV | 2012 |
|
RU2644201C2 |
| STABLE VECTOR OF CONSTITUTIVELY HIGH EXPRESSION FOR OBTAINING HPV VACCINE, AND RECOMBINANT LACTIC ACID BACTERIA TRANSFORMED BY THIS VECTOR | 2010 |
|
RU2492240C2 |
| HOMODIMER PROTEIN CONSTRUCTION | 2011 |
|
RU2624041C2 |
| POLYEPITOPE ANTI-TUMOUR VACCINE STRUCTURE CONTAINING EPITOPES OF TUMOR-ASSOCIATED ANTIGENS, PHARMACEUTICAL COMPOSITION AND ITS APPLICATION FOR STIMULATING SPECIFIC ANTI-TUMOR IMMUNE RESPONSE | 2016 |
|
RU2684235C2 |
| FUSED PROTEINS WITH IMMUNOGLOBULIN FC-FRAGMENT FOR ENHANCING IMMUNOGENICITY OF PROTEIN AND PEPTIDE ANTIGENS | 2000 |
|
RU2248214C2 |
| MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS BASED THEREON AND THEIR APPLICATION | 2012 |
|
RU2632651C2 |
| CHIMERIC ANTIBODY/T-CELL RECEPTOR STRUCTURES AND THEIR APPLICATIONS | 2016 |
|
RU2767209C2 |
| COMPOUNDS AND METHODS FOR TREATMENT AND DIAGNOSTICS OF CHLAMYDIA INFECTION | 2001 |
|
RU2410394C2 |
| CPG AMPHIPHILES AND APPLICATIONS THEREOF | 2019 |
|
RU2823677C2 |
